医药制造企业发展能力评价模型的构建与应用研究

发布时间：2018-04-25 21:27

本文选题：企业发展能力 + 医药制造企业　；参考：《北京交通大学》2017年硕士论文

【摘要】：随着全球一体化进程的不断加快和市场经济的不断发展,企业之间的竞争也不断加剧,评价和分析企业发展能力的重要性日益凸显。本文基于对企业发展能力本质的探讨,选择了具有代表性的医药制造行业展开研究。通过分析医药制造行业的发展现状和特点,总结得出医药制造企业发展能力的影响因素,构建了医药制造企业发展能力评价指标体系。运用主成分分析法,利用医药制造行业上市公司2013-2015年数据,构建了医药制造企业发展能力评价模型,计算得出整个行业的得分并进行简要分析,并利用行业数据进行了有效性检验。最后,选取了两家医药制造行业上市公司即双鹭药业和华北制药作为案例,应用该模型对两家企业的发展能力进行对比评价与分析,发掘医药制造企业发展能力存在的问题并提出建议。本文研究思路与已有研究的区别在于:(1)已有研究很少同时对企业发展能力与企业成长性、企业能力、企业竞争力等相关概念进行阐释和区分,本文基于对企业发展能力本质的探讨和相关理论的总结梳理,界定了企业发展能力和其它相关的概念,阐述了企业发展能力与其它概念的区别和联系。(2)已有研究多只进行企业发展能力模型构建,并简单地进行行业描述性分析,无法深入体现模型的应用价值。本文在构建医药制造企业发展能力评价模型并利用行业数据进行有效性检验的基础上,将模型应用于双鹭药业和华北制药两个案例。本文有以下研究发现:(1)基于企业成长理论和企业能力理论,本文认为企业发展能力是能力视角下的企业成长性(尤其是内生成长性)的体现,是指企业通过投入和运用资源形成的内部潜力和外部扩张力。(2)医药制造企业发展能力影响因素包括外部因素(经济环境、行业政策和社会健康问题)以及内部因素(人力资源、研发水平、现有经营管理水平、未来持续经营可能和企业规模),由此构建的医药制造企业发展能力评价指标体系和模型由学习创新能力、经营拓展能力、盈利能力、营运能力、偿债能力、持续经营能力和规模扩张能力等七个维度、十五个指标构成。(3)2013-2015年,医药制造企业发展能力得分主要分布在-2～2的区间范围内,且整体分布较为均匀。其中,42.19%的医药制造企业发展能力表现良好或较好。总体来看,医药制造企业发展能力仍然存在较大的提升空间。(4)医药制造企业发展能力存在着产品同质化、技术门槛低及结构单一,经营管理水平有待提高,人才储备和研发投入不足等短板,为此企业需要注重优化产品结构和产业布局,调整资本结构和加强财务管理以及提升人力资源投资水平和研发水平。本文主要创新在于:(1)基于相关研究现状和理论基础的梳理,本文对企业发展能力的概念进行了界定,对理论体系进行了整合与充实,具有一定的理论创新性。(2)基于医药制造行业发展现状和特点总结得出医药制造企业发展能力影响因素,本文由此构建了医药制造企业发展能力评价指标体系和模型。(3)通过对两家具有代表性的医药制造企业发展能力各维度进行剖析,本文发掘出医药制造企业发展能力存在的问题并提出建议。
[Abstract]:With the continuous acceleration of the global integration process and the continuous development of the market economy, the competition between enterprises is increasing. The importance of evaluating and analyzing the development ability of enterprises is becoming more and more important. Based on the discussion of the essence of the ability of enterprise development, this paper chooses a representative pharmaceutical manufacturing industry to carry out research. The current situation and characteristics of the development of the industry, summed up the influencing factors of the development ability of pharmaceutical manufacturing enterprises, and constructed the evaluation index system of the development ability of pharmaceutical manufacturing enterprises. By using the principal component analysis method and using the data of 2013-2015 years of the listed companies of pharmaceutical manufacturing industry, the evaluation model of the development ability of pharmaceutical manufacturing enterprises was constructed, and the whole calculation was calculated. The score of the industry is analyzed briefly, and the validity of the industry data is tested. Finally, two pharmaceutical industry listed companies, double Heron pharmaceutical and North China pharmaceutical, are selected as a case. The model is used to compare and analyze the development ability of the two enterprises, and to explore the existence of the development ability of the pharmaceutical manufacturing enterprises. The differences between the research ideas and the existing research are as follows: (1) there are few existing studies explaining and distinguishing the related concepts of enterprise development ability and enterprise growth, enterprise ability and enterprise competitiveness. Based on the discussion of the essence of enterprise development ability and the summary of related theories, this paper defines the enterprises' development. Ability and other related concepts, and explain the difference and connection between the ability of enterprise development and other concepts. (2) many studies have been carried out to build the model of enterprise development ability, and simply carry out industry descriptive analysis, and can not reflect the application value of the model in depth. On the basis of the validity test of the industry data, the model is applied to two cases of double Heron pharmaceutical and North China Pharmaceutical. The following studies have found that: (1) based on the theory of enterprise growth and the theory of enterprise ability, this paper thinks that the enterprise development ability is the embodiment of enterprise growth (especially endogenous growth) from the perspective of ability, which refers to the enterprise (2) the factors affecting the development capacity of pharmaceutical manufacturing enterprises include external factors (economic environment, industry policy and social health problems) and internal factors (human resources, R & D level, current management level, future sustainable management and enterprise scale), which are constructed. The development capability evaluation index system and model of pharmaceutical manufacturing enterprises are composed of seven dimensions, including learning innovation ability, business development ability, profitability, operation ability, solvency, sustainable management ability and scale expansion ability. (3) 2013-2015 years, the development ability score of medical manufacturing enterprises is mainly distributed in the range of -2 to 2. Within the scope, the overall distribution is more uniform. Among them, 42.19% of the pharmaceutical manufacturing enterprises have good or better development ability. In general, the development ability of pharmaceutical manufacturing enterprises still has a greater promotion space. (4) the development ability of pharmaceutical manufacturing enterprises is homogenized, the technical threshold is low and the structure is single, and the management level needs to be raised. The enterprises need to pay attention to optimizing the structure of products and the layout of the industry, adjust the capital structure, strengthen the financial management and improve the level of human resources investment and research and development. The main innovation of this paper is: (1) this article is based on the present situation and theoretical basis of related research. The concept of force is defined and the theoretical system has been integrated and enriched. (2) based on the development status and characteristics of the pharmaceutical manufacturing industry, the factors affecting the development ability of pharmaceutical manufacturing enterprises are summarized. This paper constructs the evaluation index system and model of the development ability of pharmaceutical manufacturing enterprises. (3) through two This paper analyzes the dimensions of the development capability of the representative pharmaceutical manufacturing enterprises, and explores the problems existing in the development capability of pharmaceutical manufacturing enterprises and puts forward some suggestions.

【学位授予单位】：北京交通大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：F426.72;F406.7

【参考文献】